Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-29 10:31:42 - browse：97697

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： The EPA's new lead rule: How one expert crunched the numbers

WSS

Lilly's Alzheimer's drug donanemab backed by FDA advisers

FDA investigates CAR

Despite FDA concern, risk that CAR

Curing rare childhood diseases will falter unless Congress steps up

As biotech industry slumps, bioscience job market is upside down

U.K. Biobank has 500,000 peoples' genome sequences available

focus

Wikipedia

explore

Hepatitis C has a cure — but many Americans still lack access to it

As biotech industry slumps, bioscience job market is upside down

In age of alternative facts, a scholarly course on calling out crap

Despite FDA concern, risk that CAR

Peter Hotez and the public health issue of online harassment

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Duchenne breakthrough therapy leaves behind pioneering families

My daughter's legacy lives on through her writing, phage therapy

Moonlake's readout produced a cash windfall. Risks remain

Teladoc has a new CEO, but challenges remain the same

entertainment

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Pharma companies must ensure equitable access to obesity drugs

Readers discuss the intersection of pregnancy and addiction

NIH tests clinical research in primary care with $30 million program

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Health care court cases: Humana, Sutter, Novant

hotspot

focus

leisure time

hotspot